Editors   FDA: NeuralStem's Fetal Stem Cell Study for Lou Gehrig's Patients on Hold   2/25/2009 9:50:00 AM    
The US FDA put a hold on NeuralStem's clinical study amyotrophic lateral sclerosis, more commonly known as Lou Gehrig’s Disease.

The company had intended to test its ability to safely inject fetal stem cells into the spinal cords of patients and fully replace the damaged spinal cord cells.

See Editors   First Human Trials for Stem Cell Therapy on Lou Gehrig Patients   12/18/2008 11:56:00 AM    
The US FDA has cleared the way for Neuralstem, Inc. to conduct clinical trials on ALS (Lou Gehrig's disease) patients by injecting stem cells into their spinal cord.